Together, these findings demonstrate that intravenous delivery of CpG7909 lipoplex mitigates the systemic toxicities commonly associated with TLR9 agonists while maintaining potent immune activation, thereby confirming its safety, tolerability, and ability to overcome the major limitations of intratumoral administration for metastatic tumors. The gene discussed is TLR9; the disease is metastatic neoplasm.